CCL13/MCP-4 belongs to the CC chemokine family, which induces chemotaxis in many immune cells. Despite extensive research into its function in numerous disorders, a thorough analysis of CCL13 is not yet accessible. The role of CCL13 in human disorders and existing CCL13-focused therapies are outlined in this study. The function of CCL13 in rheumatic diseases, skin conditions, and cancer is comparatively well-established, and some studies also suggest that it may be involved in ocular disorders, orthopedic conditions, nasal polyps, and obesity. We also give an overview of research that found very little evidence of CCL13 in HIV, nephritis, and multiple sclerosis. Even though CCL13-mediated inflammation is frequently linked to disease pathogenesis, it’s fascinating to note that in some conditions, like primary biliary cholangitis (PBC) and suicide, it might even act as a preventative measure.
Background: This study was to explore the relationship between chronic constipation, chronic diarrhea, and frailty in older Americans. Methods: This cross-sectional study selected a total of 4241 community-dwelling individuals aged 60 years and older from the 2005–2010 National Health and Nutrition Examination Survey. Frailty was measured using a 49-item frailty index, and a frailty index > 0.21 was defined as a frail status. Chronic constipation and chronic diarrhea were defined as the “usual or most common type of stool” by the Bristol Stool Form Scale (BSFS) Types 1 and 2 and BSFS Types 6 and 7, respectively. Weighted logistic regression analysis was used to examine the relationship between gut health and frailty status. Restricted cubic spline (RCS) curves were built to assess the association between frailty index and stool frequency. Results: Frailty status was associated with higher odds of constipation in an unadjusted model; however, after further adjusting for confounding variables, the relationship between frailty status and constipation was not statistically significant. We discovered a positive correlation between the frailty status and diarrhea after adjustment for all variables. The frailty index showed a U-shaped relationship with stool frequency, and the frailty index was the smallest at a frequency of 10 stools/week. Conclusion: Negative associations were observed between frailty status and chronic constipation and diarrhea among older adults. Older adults who have a bowel movement frequency of about 10 times per week are the least frail. Future studies are warranted to confirm the causal relationship in this association.
7 May 2024 in Clinical and Translational Gastroenterology
INTRODUCTION: Constipation is an independent risk factor for poor bowel preparation. This study aimed to evaluate the bowel cleansing efficacy and safety of polyethylene glycol (PEG) combined with linaclotide (lin) for colonoscopy in patients with chronic constipation (CC). METHODS: This single-blinded, randomized, controlled, and multicenter study was conducted from July 2021 to December 2022 at 7 hospitals. Patients with CC who underwent colonoscopies were enrolled and randomly assigned to 4 groups with split-PEG regimens: 4L-PEG group, 4L-PEG+1d-Lin group, 3L-PEG+1d-Lin group, and 3L-PEG+3d-Lin group. The primary outcome was rates of adequate bowel preparation, defined as a total BBPS score ≥6 and a score ≥2 for each segment. Secondary outcomes were adverse effects, sleep quality, willingness to repeat the colonoscopy, adenoma detection rate, and polyp detection rate. RESULTS: Five hundred two patients were enrolled. The rates of adequate bowel preparation (80.0% vs 60.3%, P < 0.001; 84.4% vs 60.3%, P < 0.001) and the total Boston Bowel Preparation Scale (BBPS) scores (6.90 ± 1.28 vs 6.00 ± 1.61, P < 0.001; 7.03 ± 1.24 vs 6.00 ± 1.61, P < 0.01) in the 4L-PEG+1d-Lin group and the 3L-PEG+3d-Lin group were superior to that in the 4L-PEG group. Compared with the 4L-PEG group, the 4L-PEG+1d-Lin group (66.7% vs 81.7%, P = 0.008) and the 3L-PEG+3d-Lin group (75.0% vs 81.7%, P = 0.224) had a lower percentage of mild adverse events. No statistically significant difference in willingness to repeat the colonoscopy, sleep quality, polyp detection rate, or adenoma detection rate was observed among groups. DISCUSSION: PEG combined with linaclotide might be an effective method for bowel preparation before colonoscopy in patients with CC.
1 January 2022 in International Journal of Biological Sciences
Objective: The treatment and prognosis of patients with advanced colorectal cancer (CRC) remain a difficult problem. Herein, we investigated the role of DEAD (Asp-Glu-Ala-Asp) box helicase 3 (DDX3) in CRC and proposed potential therapeutic targets for advanced CRC.
4 September 2025 in International Journal of Surgery
Background: Functional dyspepsia (FD) is often comorbid with sleep disturbance. Transcutaneous auricular vagal nerve stimulation (taVNS) is a new and non-invasive therapeutic option. This study aimed to investigate its effects and possible mechanisms on FD with sleep disturbance. Methods: This was a prospective, single-center, single-blind, and randomized controlled trial. Fifty-four FD patients with sleep disturbance were randomly divided to receive 4-week taVNS or transcutaneous non-vagal nerve stimulation (tnVNS). The primary outcomes included Nepean Dyspepsia Index Symptom (NDIS) and Pittsburgh Sleep Quality Index (PSQI). The secondary outcomes were composed of Nepean Dyspepsia Index Quality of Life (NDIQOL), Hamilton Anxiety (HAMA), Depression (HAMD), autonomic functions, gastric slow waves, gastric accommodation, and serum melatonin. Results: Compared with tnVNS: (1) taVNS resulted in a lower NDIS and PSQI scores ( P < 0.05); it also reduced HAMD and HAMA scores but increased NDIQOL score ( P < 0.05). (2) taVNS increased the percentage of normal gastric slow waves (NSW%), the maximum tolerable volume, the serum melatonin level, and the high-frequency (HF, reflecting vagal activity) component in the fasting state ( P < 0.05). In taVNS group, the HF in the fasting state was positively correlated with the NSW% and the melatonin level. Conclusion: taVNS is effective and safe for the treatment of FD with sleep disturbance. The effect may be attributed to the dual neuromodulating effects of taVNS on both the gut and the brain via enhanced vagal activity.